• Ultragenyx Pharmaceutical recently reported that the FDA has accepted for review its resubmitted BLA for UX111, an AAV9 gene therapy for Sanfilippo syndrome Type A (MPS IIIA), with a PDUFA action date set for September 19, 2026.
• The filing includes up to eight years of follow-up data suggesting durable clinical and biomarker effects in a disease with no approved treatments, highlighting UX111’s potential importance for a small but severely affected patient population.
• With UX111 now under FDA review and supported by long-term data, we’ll examine how this milestone could reshape Ultragenyx’s investment narrative.

AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Ultragenyx Pharmaceutical Investment Narrative Recap

To own Ultragenyx, you need to believe that its rare disease gene therapy portfolio will eventually support a path to profitability despite ongoing losses and high R&D spend. The UX111 BLA acceptance gives the company a clearer regulatory path on one of its key programs and helps address prior CMC-related delays, but it does not remove the near term risk around cash burn and potential dilution as Ultragenyx invests ahead of possible approvals.

Among recent updates, the FDA’s Priority Review of DTX401 for glycogen storage disease Type Ia, with an August 23, 2026 PDUFA date, stands out alongside UX111. Together, these late stage gene therapy filings frame the next 12 to 18 months as a period where multiple regulatory outcomes could influence Ultragenyx’s revenue mix, its dependence on existing products, and its ability to move closer to its stated profitability goals.

However, investors should also be aware that if UX111 or DTX401 face fresh regulatory setbacks or commercial hurdles, the combination of persistent losses, legal overhangs, and pressure on funding options could...

Ultragenyx Pharmaceutical's narrative projects $1.3 billion revenue and $69.1 million earnings by 2029.

Uncover how Ultragenyx Pharmaceutical's forecasts yield a $52.45 fair value, a 119% upside to its current price.

Exploring Other Perspectives

The most cautious analysts were modeling only about 14.6% annual revenue growth to roughly US$918.1 million and no profits by 2028 before this UX111 update, so you should recognize how differently risk can be viewed and consider how fresh regulatory progress or setbacks on UX111 might shift both that outlook and your own.

Explore 2 other fair value estimates on Ultragenyx Pharmaceutical - why the stock might be worth just $52.45!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ultragenyx Pharmaceutical research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Ultragenyx Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ultragenyx Pharmaceutical's overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find 62 companies with promising cash flow potential yet trading below their fair value.
• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.